

101.567-12 – including *Taq* polymerase  
101.567-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **2S2**

Lot-specific information  
**Olerup SSP® HLA-B\*57**

<b>Product number:</b>	101.567-12 – including <i>Taq</i> polymerase 101.567-12u – without <i>Taq</i> polymerase
<b>Lot number:</b>	2S2
<b>Expiry date:</b>	2027-07-01
<b>Number of tests:</b>	12
<b>Number of wells per test:</b>	31+1
<b>Storage - pre-aliquoted primers:</b>	dark, between -15°C and -25°C
- PCR Master Mix:	between -15°C and -25°C
- Adhesive PCR seals	RT

**This Product Description is only valid for Lot No. 2S2.**

Complete product documentation consists of generic Instructions for Use (IFU), lot specific Product Insert, Worksheet and Certificate.

**CHANGES COMPARED TO THE PREVIOUS OLERUP SSP®  
HLA-B\*57 LOT (6N7)**

- The product documentation has been updated for new alleles of IMGT 3.52.0
- The kit resolution focuses on common and well documented (CWD) alleles<sup>1</sup>.

<sup>1</sup>As described in section Uniquely Identified Alleles.

The HLA-B\*57 specificity and interpretation tables have been updated for the HLA-B alleles described since the previous *Olerup SSP®* HLA-B\*57 lot was made (**Lot No. 6N7**).

The primers of the wells detailed below have been exchanged, added or modified compared to the previous lot.

Well	5'-primer	3'-primer	rationale
9	-	-	Exchanged positive control primer pair for decreased tendencies of primer oligomer formation.

<sup>1</sup>S. J. Mack, P. Cano, J. A. Hollenbach et al.  
Common and well-documented HLA alleles: 2012 update to the CWD catalogue. *Tissue Antigens*, 2013, 81, 194–203



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: July 2023, Rev. No:00

101.567-12 – including *Taq* polymerase  
101.567-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **2S2**

**Lot-specific information**

Well **32** contains Negative Control primer pairs, that will amplify the majority of the *Olerup SSP*® HLA Class I, DRB, DQB1, DPB1 and DQA1 amplicons as well as all the amplicons generated by the control primer pairs matching the human growth hormone gene.

HLA-specific PCR product sizes range from 75 to 200 base pairs.

The PCR product generated by the positive control primer pair is 200 base pairs.

Length of PCR product	105	200	105	80	75	80	85
<b>5'-primer<sup>1</sup></b>	<b>164</b>	<b>340</b>	<b>440</b>	<b>45</b>	<b>45</b>	<b>43</b>	<b>36</b>
	5'-CAC <sup>3'</sup>	5'-Agg <sup>3'</sup>	5'-TTA <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-TAC <sup>3'</sup>
							<b>36</b>
							5'-TAT <sup>3'</sup>
<b>3'-primer<sup>2</sup></b>	<b>231</b>	<b>2<sup>nd</sup> I</b>	<b>507</b>	<b>59</b>	<b>58</b>	<b>57</b>	<b>47</b>
	5'-TgC <sup>3'</sup>	5'-AAA <sup>3'</sup>	5'-TTg <sup>3'</sup>	5'-CTC <sup>3'</sup>	5'-ggC <sup>3'</sup>	5'-CTC <sup>3'</sup>	5'-ACA <sup>3'</sup>
							<b>48</b>
							5'-gCA <sup>3'</sup>
							<b>48</b>
							5'-gCC <sup>3'</sup>
							<b>52</b>
							5'-TgT <sup>3'</sup>
<b>A*</b>	<b>+</b>	<b>+</b>	<b>+</b>				
<b>B*</b>	<b>+</b>	<b>+</b>	<b>+</b>				
<b>C*</b>	<b>+</b>	<b>+</b>	<b>+</b>				
<b>DRB1</b>				<b>+</b>	<b>+</b>		
<b>DRB3</b>				<b>+</b>	<b>+</b>		
<b>DRB5</b>				<b>+</b>			
<b>DQB1</b>					<b>+</b>		
<b>DPB1</b>						<b>+</b>	
<b>DQA1</b>							<b>+</b>

<sup>1</sup>The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2<sup>nd</sup> or 3<sup>rd</sup> exon, matching the specificity-determining 3'-end of the primer is given. Nucleotide and codon numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

<sup>2</sup>The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2<sup>nd</sup> or 3<sup>rd</sup> exon or the 2<sup>nd</sup> intron, matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide and codon numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: July 2023, Rev. No:00

101.567-12 – including *Taq* polymerase  
101.567-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **2S2**

Lot-specific information  
**PRODUCT DESCRIPTION**

**HLA-B\*57 SSP subtyping**

**CONTENT**

The primer set contains 5'- and 3'-primers for identifying the B\*57:01 to B\*57:167 alleles.

**PLATE LAYOUT**

Each test consists of 32 PCR reactions in a 32 well cut PCR plate.

<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>8</b>
<b>9</b>	<b>10</b>	<b>11</b>	<b>12</b>	<b>13</b>	<b>14</b>	<b>15</b>	<b>16</b>
<b>17</b>	<b>18</b>	<b>19</b>	<b>20</b>	<b>21</b>	<b>22</b>	<b>23</b>	<b>24</b>
<b>25</b>	<b>26</b>	<b>27</b>	<b>28</b>	<b>29</b>	<b>30</b>	<b>31</b>	<b>NC</b>

The 32 well cut PCR plate is marked with ‘HLA-B\*57’ in silver/gray ink.

Well No. 1 is marked with the Lot No. ‘2S2’.

Wells 1 to 31 – HLA-B\*57 high resolution primers.

Well 32 – Negative Control (NC).

A faint row of numbers is seen between wells 1 and 2 or wells 7 and 8 of the PCR trays. These stem from the manufacture of the trays and should be disregarded.

The PCR plates are heat-sealed with a PCR-compatible foil.

**Please note:** When removing each 32 well PCR plate, make sure that the remaining plates stay sealed. Use a scalpel or a similar instrument to carefully cut the foil between the plates.

**INTERPRETATION**

Due to the sharing of sequence motifs between HLA-B alleles non-HLA-B\*57 alleles will be amplified by some primer mixes. For further details see Specificity Table.

**UNIQUELY IDENTIFIED ALLELES**

All the HLA-B\*57 alleles, i.e. **B\*57:01 to B\*57:167**, recognized by the HLA Nomenclature Committee in April 2023<sup>1,2</sup> will be amplified by the primers in the HLA-B\*57 subtyping kit.

The HLA-B\*57 kit enables separation of the confirmed HLA-B\*57 alleles as listed in the IMGT/HLA database 3.25.0. An HLA allele is listed as confirmed by IMGT/HLA if it has been sequenced by more than a single laboratory or from multiple sources. Current allele confirmation status for HLA-B\*57 alleles is listed below.

The HLA-B\*57 kit also enables identification of many null and alternatively expressed alleles.



**0197**

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: July 2023, Rev. No:00

101.567-12 – including *Taq* polymerase  
101.567-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **2S2**

Lot-specific information

The following HLA-B\*57 alleles can be distinguished by the different sizes of the HLA-specific PCR product:

Alleles	Primer mix
B*57:15, 57:37, 57:55	7
B*57:25, 57:41	19

<sup>1</sup>HLA-B alleles listed on the IMGT/HLA web page 2023-April-17 release 3.52.0, [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla).

<sup>2</sup>Alleles that have been deleted from or renamed in the official WHO HLA Nomenclature up to and including the last IMGT/HLA database release can be retrieved from web page <http://hla.alleles.org/alleles/deleted.html>.

### ALLELE CONFIRMATION STATUS

Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>
<b>B*57:01:01</b>	<b>Confirmed</b>	B*57:06	Unconfirmed	<b>B*57:35</b>	<b>Confirmed</b>	B*57:65	Unconfirmed
B*57:01:02	Unconfirmed	B*57:07	Unconfirmed	B*57:36	Unconfirmed	B*57:66	Unconfirmed
B*57:01:03	Unconfirmed	B*57:08	Unconfirmed	B*57:37	Unconfirmed	B*57:67:01	Unconfirmed
B*57:01:04	Unconfirmed	<b>B*57:09</b>	<b>Confirmed</b>	B*57:38	Unconfirmed	B*57:67:02	Unconfirmed
<b>B*57:01:05</b>	<b>Confirmed</b>	B*57:10	Unconfirmed	<b>B*57:39</b>	<b>Confirmed</b>	B*57:68	Unconfirmed
B*57:01:06	Unconfirmed	<b>B*57:11</b>	<b>Confirmed</b>	<b>B*57:40</b>	<b>Confirmed</b>	B*57:69	Unconfirmed
<b>B*57:01:07</b>	<b>Confirmed</b>	B*57:12	Unconfirmed	<b>B*57:41</b>	<b>Confirmed</b>	B*57:70	Unconfirmed
<b>B*57:01:08</b>	<b>Confirmed</b>	<b>B*57:13</b>	<b>Confirmed</b>	B*57:42	Unconfirmed	B*57:71	Unconfirmed
B*57:01:09	Unconfirmed	<b>B*57:14:01</b>	<b>Confirmed</b>	<b>B*57:43</b>	<b>Confirmed</b>	B*57:72	Unconfirmed
<b>B*57:01:10</b>	<b>Confirmed</b>	B*57:14:02	Unconfirmed	<b>B*57:44</b>	<b>Confirmed</b>	<b>B*57:73</b>	<b>Confirmed</b>
B*57:01:11	Unconfirmed	<b>B*57:15</b>	<b>Confirmed</b>	B*57:45	Unconfirmed	B*57:74	Unconfirmed
B*57:01:12	Unconfirmed	B*57:16	Unconfirmed	B*57:46	Unconfirmed	B*57:75	Unconfirmed
B*57:01:13	Unconfirmed	<b>B*57:17</b>	<b>Confirmed</b>	B*57:47	Unconfirmed	B*57:76	Unconfirmed
<b>B*57:01:14</b>	<b>Confirmed</b>	B*57:18	Unconfirmed	B*57:48	Unconfirmed	<b>B*57:77</b>	<b>Confirmed</b>
B*57:01:15	Unconfirmed	B*57:19	Unconfirmed	<b>B*57:49</b>	<b>Confirmed</b>	<b>B*57:78</b>	<b>Confirmed</b>
B*57:01:16	Unconfirmed	<b>B*57:20</b>	<b>Confirmed</b>	B*57:50	Unconfirmed	B*57:79N	Unconfirmed
B*57:01:17	Unconfirmed	<b>B*57:21</b>	<b>Confirmed</b>	B*57:51	Unconfirmed	B*57:80	Unconfirmed
B*57:01:18	Unconfirmed	<b>B*57:22</b>	<b>Confirmed</b>	B*57:52	Unconfirmed	B*57:81	Unconfirmed
B*57:01:19	Unconfirmed	<b>B*57:23</b>	<b>Confirmed</b>	B*57:53	Unconfirmed	B*57:82	Unconfirmed
B*57:01:20	Unconfirmed	<b>B*57:24</b>	<b>Confirmed</b>	B*57:54	Unconfirmed	B*57:83	Unconfirmed
B*57:01:21	Unconfirmed	B*57:25	Unconfirmed	B*57:55	Unconfirmed		
B*57:01:22	Unconfirmed	<b>B*57:26</b>	<b>Confirmed</b>	B*57:56	Unconfirmed		
<b>B*57:02:01</b>	<b>Confirmed</b>	B*57:27	Unconfirmed	<b>B*57:57</b>	<b>Confirmed</b>		
<b>B*57:02:02</b>	<b>Confirmed</b>	B*57:28N	Unconfirmed	<b>B*57:58</b>	<b>Confirmed</b>		
<b>B*57:03:01:01</b>	<b>Confirmed</b>	<b>B*57:29</b>	<b>Confirmed</b>	B*57:59	Unconfirmed		
B*57:03:01:02	Unconfirmed	B*57:30	Unconfirmed	B*57:60	Unconfirmed		
B*57:03:02	Unconfirmed	B*57:31	Unconfirmed	<b>B*57:61</b>	<b>Confirmed</b>		
<b>B*57:04:01</b>	<b>Confirmed</b>	<b>B*57:32</b>	<b>Confirmed</b>	B*57:62	Unconfirmed		
B*57:04:02	Unconfirmed	B*57:33	Unconfirmed	<b>B*57:63</b>	<b>Confirmed</b>		
<b>B*57:05</b>	<b>Confirmed</b>	<b>B*57:34</b>	<b>Confirmed</b>	B*57:64	Unconfirmed		

<sup>1</sup>Allele status “confirmed” or “unconfirmed” as listed on the IMGT/HLA web page 2016-July-14, release 3.25.0, [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla).

### RESOLUTION IN HOMO- AND HETEROZYGOTES

Results file with resolution in HLA-B\*57 homo- and heterozygotes is available upon request.



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: July 2023, Rev. No:00

101.567-12 – including *Taq* polymerase  
101.567-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **2S2**

Lot-specific information  
**SPECIFICITY TABLE**

**HLA-B\*57 SSP subtyping**

Specificities and sizes of the PCR products of the 31+1 primer mixes used for  
HLA-B\*57 SSP subtyping

Primer Mix	Size of spec. PCR product <sup>1</sup>	Size of control band <sup>2</sup>	Amplified HLA-B*57 alleles <sup>3</sup>	Other amplified HLA Class I alleles
1	150 bp	800 bp	*57:01:01:01-57:01:04, 57:01:06-57:10, 57:12, 57:14:01-57:30, 57:32-57:46, 57:48-57:73, 57:75-57:81, 57:84-57:117, 57:119-57:144, 57:146-57:167	*07:235, 07:359, 08:49, 08:255, 13:01:01:01-13:01:22, 13:06-13:07N, 13:12:01-13:13:02, 13:17, 13:20, 13:22:01-13:23, 13:25-13:26:02, 13:28-13:29, 13:36, 13:39, 13:43, 13:50-13:52, 13:57, 13:60-13:61, 13:63N, 13:73, 13:76N-13:80, 13:83, 13:86-13:87, 13:90, 13:92, 13:95, 13:106-13:107, 13:109-13:110, 13:122, 13:129, 13:135, 13:138, 13:141-13:142, 13:144, 13:146, 13:148, 13:161N-13:163, 13:168, 13:170-13:171, 13:173, 14:10, 14:102, 15:02:01:01-15:02:13, 15:13:01-15:13:03, 15:20-15:21:01:02, 15:25:01:01-15:25:04, 15:36, 15:44, 15:62, 15:77, 15:80, 15:85, 15:88-15:89:02, 15:106, 15:112, 15:121, 15:139, 15:144, 15:154, 15:165, 15:170, 15:194, 15:204, 15:213-15:214, 15:223, 15:240, 15:250, 15:265, 15:271, 15:283, 15:289, 15:291, 15:297, 15:301-15:302N, 15:308, 15:319, 15:325, 15:328, 15:330, 15:341, 15:345, 15:357-15:358, 15:366, 15:374, 15:378, 15:393-15:394, 15:399, 15:402, 15:404, 15:407, 15:418, 15:420, 15:425, 15:437-15:438, 15:454N, 15:458, 15:460, 15:463N, 15:468, 15:491, 15:495, 15:505, 15:537, 15:543-15:544N, 15:557, 15:564, 15:566-15:567, 15:569, 15:574, 15:584N, 15:587, 15:589, 15:592, 15:594, 15:596N, 15:599, 15:615, 15:623, 15:625, 15:627, 15:630, 15:645-15:646, 15:648, 15:654, 15:657-15:659, 15:664, 18:22, 18:69, 18:105, 18:149-18:150, 18:204, 27:19:01:01-27:19:01:02, 27:30, 27:127, 27:150, 35:01:01:01-35:01:54, 35:01:56-35:01:61, 35:01:63-35:04:03, 35:06-35:08:15, 35:10-35:17:04, 35:19-35:21, 35:23-35:30:01:02, 35:33-35:36, 35:38-35:42:02, 35:45-35:50, 35:52, 35:54-35:57, 35:59:01-35:59:02, 35:61:01-35:63, 35:65Q, 35:69-35:71, 35:74, 35:76-35:78, 35:80-35:85, 35:90-35:96, 35:98, 35:100-35:101:02, 35:103-35:113, 35:115-35:116, 35:120-35:126, 35:128-35:134N, 35:136-35:150:02, 35:152-35:173:02N, 35:175-35:184, 35:186-35:198,



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: July 2023, Rev. No:00

101.567-12 – including *Taq* polymerase  
101.567-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **2S2**

Lot-specific information

				35:200-35:204, 35:206-35:229, 35:231, 35:233, 35:236-35:250, 35:252-35:259, 35:261-35:264, 35:266-35:272, 35:274-35:275, 35:277-35:291, 35:293-35:320, 35:322-35:330, 35:332-35:366, 35:370-35:371, 35:373-35:388, 35:390N-35:408, 35:410-35:415, 35:417-35:426, 35:428Q-35:432, 35:434-35:439:01:02, 35:441-35:458, 35:460Q-35:470, 35:473-35:474, 35:477-35:480, 35:482-35:497, 35:500-35:508N, 35:510-35:518, 35:520, 35:522, 35:524-35:533, 35:536-35:538, 35:540, 35:542N-35:548, 35:550-35:571, 35:573-35:577, 37:01:01:01-37:01:07, 37:01:09, 37:01:11-37:01:31, 37:03N-37:06:02, 37:08, 37:10-37:11, 37:13-37:43, 37:45-37:50, 37:52-37:80, 37:82N-37:107, 38:20:01-38:20:02, 39:42, 39:195, 40:28, 40:458, 44:02:01:01-44:02:33, 44:02:35-44:02:57, 44:02:59-44:14, 44:16-44:17, 44:19N, 44:21-44:30, 44:32-44:40, 44:42-44:46:02, 44:48:01-44:52N, 44:55-44:64:02, 44:66-44:98, 44:101-44:105, 44:107-44:134, 44:136-44:137, 44:139-44:157, 44:159-44:165, 44:167-44:181, 44:183, 44:185-44:191, 44:194:01-44:196, 44:198N-44:212, 44:214-44:229, 44:231-44:235, 44:237N-44:245:02, 44:247-44:304, 44:306N-44:338, 44:340-44:342, 44:344-44:354N, 44:356-44:373, 44:437-44:439, 44:441-44:458, 44:460-44:490, 44:492-44:505, 44:507-44:517, 44:519-44:524, 44:526-44:546, 46:33, 46:67, 48:02:01-48:02:03, 48:25, 49:61, 50:17, 51:04:01-51:04:02, 51:42, 51:46, 51:56:01-51:56:03, 51:139, 51:227, 51:281, 51:310, 51:359, 52:88, 53:01:01:01-53:13, 53:15-53:40, 53:42-53:43:02, 53:45-53:46, 53:48N-53:66, 53:68-53:72, 55:14, 56:09, 56:11-56:12, 56:60, 58:01:01:01-58:01:02, 58:01:04-58:01:15, 58:01:17-58:01:45, 58:04-58:05, 58:09-58:15, 58:17N, 58:19, 58:21-58:24, 58:28:01-58:29, 58:31N-58:37, 58:39N-58:42, 58:44-58:45:02, 58:47-58:59:02, 58:62-58:103, 58:105-58:120, 58:123-58:126, 58:128N-58:131, 58:133N-58:143, 83:01, <b>C*03:102, C*03:263:01-03:263:03, C*03:514, C*15:126</b>
2 <sup>4</sup>	100 bp	1070 bp	*57:01:01:01-57:01:46, 57:06, 57:08, 57:10, 57:13-57:16, 57:18-57:27, 57:29-57:31:02, 57:33-57:38, 57:40 <sup>w</sup> , 57:41, 57:43-57:45, 57:47-57:52, 57:54-57:56, 57:58-57:62, 57:64-57:65,	*35:208:01-35:208:02, 35:317, 37:94, 55:14, 58:14, <b>C*06:72</b>



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: July 2023, Rev. No:00

101.567-12 – including *Taq* polymerase  
101.567-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **2S2**

Lot-specific information

Lot No.: <b>2S2</b>			Lot-specific information	
			57:67:01-57:69, 57:71-57:75, 57:77-57:79N, 57:81, 57:85-57:93, 57:95, 57:97-57:98Q, 57:100, 57:102-57:111, 57:113-57:117, 57:119-57:123, 57:125-57:130N, 57:132-57:133, 57:135-57:136, 57:138-57:154, 57:156-57:159, 57:161-57:167	
<b>3</b>	220 bp	1070 bp	*57:01:01:01-57:01:46, 57:03:01:01-57:03:06, 57:06-57:08, 57:10, 57:14:01-57:18, 57:20-57:23, 57:25-57:27, 57:29, 57:31:01-57:41, 57:43-57:51, 57:53-57:60, 57:62, 57:64-57:81, 57:84-57:98Q, 57:100-57:111, 57:113-57:117, 57:120-57:128, 57:130N, 57:132-57:133, 57:135-57:139N, 57:141-57:146, 57:148-57:159, 57:162N-57:167	*35:208:01-35:208:02, 35:317, 37:94, 40:30, 40:34, 44:153, 55:14, 58:14
<b>4<sup>4</sup></b>	100 bp	<b>800 bp</b>	*57:02:01:01-57:03:06, 57:05, 57:07, 57:09, 57:12, 57:17, 57:39, 57:42, 57:46, 57:57, 57:63, 57:66, 57:70, 57:80, 57:84, 57:94, 57:96, 57:101, 57:124, 57:137, 57:155	*07:137, 08:60, 08:76 <sup>w</sup> , 08:129, 08:181, 13:13:01-13:13:02, 13:21, 13:86, 35:02:01:01-35:02:20, 35:04:01:01-35:04:03, 35:06 <sup>w</sup> , 35:09:01:01-35:09:04, 35:12:01:01-35:12:04, 35:18, 35:59:01 <sup>w</sup> , 35:81, 35:83, 35:88, 35:95, 35:129N, 35:149, 35:154, 35:157, 35:162, 35:172, 35:182-35:184, 35:201, 35:211, 35:220, 35:230, 35:233, 35:258, 35:266, 35:270, 35:285, 35:309, 35:311, 35:316, 35:321, 35:323:01-35:323:02, 35:335, 35:339, 35:357, 35:361, 35:366, 35:372, 35:374, 35:377-35:379, 35:384, 35:387, 35:391, 35:396, 35:403, 35:410, 35:419, 35:425, 35:443, 35:463, 35:468, 35:474, 35:477, 35:483, 35:487, 35:492, 35:501, 35:505, 35:508N, 35:522, 35:539, 35:550, 35:553, 35:555, 35:557, 35:562, 35:565, 35:569, 35:571, 37:01:01:01 <sup>w</sup> -37:01:31 <sup>w</sup> , 37:03N <sup>w</sup> -37:06:02 <sup>w</sup> , 37:08 <sup>w</sup> , 37:10 <sup>w</sup> -37:11 <sup>w</sup> , 37:12, 37:13 <sup>w</sup> -37:18 <sup>w</sup> , 37:19:01-37:19:02, 37:20 <sup>w</sup> -37:24 <sup>w</sup> , 37:26 <sup>w</sup> -37:34 <sup>w</sup> , 37:36 <sup>w</sup> -37:43 <sup>w</sup> , 37:45 <sup>w</sup> -37:50 <sup>w</sup> , 37:52 <sup>w</sup> -37:93 <sup>w</sup> , 37:94, 37:95 <sup>w</sup> -37:107 <sup>w</sup> , 38:20:01 <sup>w</sup> , 39:42 <sup>w</sup> , 40:04:01:01-40:04:02, 40:28, 40:30, 40:34,



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: July 2023, Rev. No:00

101.567-12 – including *Taq* polymerase  
101.567-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **2S2**

Lot-specific information

Lot No.: <b>2S2</b>		Lot-specific information	
			40:64:01:01-40:64:02, 40:68, 40:99 <sup>w</sup> , 40:129, 40:137, 40:160:01-40:160:02, 40:343, 40:535, 41:48, 42:13, 44:62, 44:77, 44:82 <sup>w</sup> , 48:17 <sup>w</sup> , 51:04:01-51:04:02, 51:46, 51:56:01-51:56:03, 51:139, 51:310, 53:19, 53:36, 56:12, 58:28:01-58:28:02, 58:65, <b>C*03:317, C*03:382, C*05:10<sup>w</sup>, C*15:24</b>
<b>5</b>	220 bp	1070 bp	*57:02:01:01-57:02:02, *07:227, <b>C*06:72</b> 57:04:01-57:04:03, 57:12-57:13, 57:19, 57:28N, 57:30, 57:42, 57:63, 57:147, 57:161
<b>6<sup>4</sup></b>	95 bp	1070 bp	*57:04:01-57:04:03, *44:153 57:32 *57:06 *57:30, 57:129
<b>7<sup>4</sup></b>	180 bp 205 bp 105 bp 170 bp 295 bp	1070 bp	*57:15 *57:37 *57:55, 57:94 *14:104, 44:517
<b>8<sup>4</sup></b>	90 bp 200 bp 250 bp	1070 bp	*57:16 *57:49 *57:07, 57:93, 57:119 *44:153
<b>9<sup>5</sup></b>	170 bp	<b>800 bp</b>	*57:09, 57:13, 57:22, *07:02:01:01-07:02:05, 07:02:07-07:24, 57:57, 57:63, 57:161 07:26-07:47, 07:49N-07:50, 07:52-07:154, 07:156-07:163, 07:165-07:201N, 07:203- 07:208, 07:210-07:219, 07:221-07:222, 07:224-07:225, 07:227-07:234, 07:236- 07:260, 07:262:01-07:300, 07:302-07:331, 07:333-07:345, 07:347-07:358, 07:360Q- 07:362, 07:364-07:385, 07:387-07:406, 07:409-07:410, 07:412-07:419, 07:421- 07:449, 07:451-07:478, 08:20:01-08:20:02, 08:53:01-08:53:02, 08:79:01-08:79:02, 08:156, 08:281, 08:296, 13:16, 13:20, 13:31, 13:48, 13:62, 13:128, 13:131, 13:145, 13:174, 13:178, 14:01:01:01-14:40, 14:42:01-14:42:02, 14:44-14:55, 14:57- 14:58, 14:60-14:89, 14:91-14:119, 15:01:01:01-15:01:04, 15:01:06-15:04:04, 15:06-15:17:04, 15:17:06-15:19, 15:21:01:01-15:21:01:02, 15:23-15:30:01:03, 15:32:01-15:40:02, 15:42-15:47:02, 15:49- 15:50, 15:53-15:54, 15:56-15:58, 15:60- 15:74, 15:76-15:82, 15:85, 15:87, 15:89:01- 15:90, 15:92-15:99, 15:101-15:104, 15:106, 15:108-15:110, 15:112-15:113, 15:115- 15:122, 15:125:01-15:129, 15:131-15:135, 15:137-15:144, 15:146-15:150, 15:152- 15:154, 15:156-15:161, 15:163-15:175, 15:177-15:178, 15:180-15:184, 15:187, 15:189:01-15:199, 15:201-15:217, 15:219- 15:221, 15:223, 15:225-15:234, 15:236, 15:238-15:249, 15:251:01-15:274, 15:276- 15:282, 15:284-15:311, 15:313-15:331, 15:333-15:347, 15:349:01-15:382,



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: July 2023, Rev. No:00



101.567-12 – including *Taq* polymerase  
101.567-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **2S2**

Lot-specific information

15:384:01-15:392, 15:394-15:395, 15:397-15:406, 15:408-15:410, 15:412-15:414, 15:416-15:420, 15:422-15:448, 15:450-15:484, 15:486-15:498, 15:500-15:506, 15:508-15:517, 15:519-15:538, 15:540N-15:551, 15:553-15:576, 15:579-15:586, 15:588-15:598, 15:600-15:622, 15:624-15:627, 15:629-15:632, 15:634-15:635, 15:637-15:665, 18:15, 18:19, 18:21, 18:30, 18:57:01-18:57:02, 18:101, 18:152, 18:164, 27:04:01-27:04:06, 27:06:01:01-27:06:02, 27:10, 27:15, 27:18, 27:20-27:21:02, 27:24-27:25, 27:40, 27:54, 27:63, 27:66N, 27:68-27:69, 27:79, 27:86, 27:91-27:92, 27:100, 27:103, 27:105-27:109, 27:112-27:115, 27:120, 27:138, 27:149, 27:153, 27:165, 27:168, 27:173, 27:183, 27:192, 27:208, 27:210-27:211, 27:214, 27:222, 27:226, 27:229, 27:240, 27:245, 27:247, 27:257, 27:262, 35:11:01-35:11:03, 35:14:01-35:14:03, 35:21, 35:43:01, 35:43:03-35:44, 35:58, 35:67, 35:79, 35:86, 35:96, 35:99, 35:102, 35:117-35:118, 35:135, 35:167, 35:185, 35:188, 35:213, 35:232, 35:265, 35:277, 35:337:01-35:337:02, 35:343, 35:384, 35:390N, 35:413, 35:439:01:01-35:439:01:02, 35:475-35:476, 35:512, 35:519, 35:549, 35:578, 37:07, 37:13, 37:97, 38:10, 38:32, 38:98, 38:106, 39:18, 39:35-39:36, 39:107, 40:05:01:01-40:05:02, 40:15-40:16:01:02, 40:23, 40:26, 40:28, 40:32, 40:51, 40:95, 40:98, 40:148, 40:158, 40:161, 40:174, 40:183, 40:198, 40:309, 40:355, 40:466, 40:496, 42:19, 44:76, 44:79:01-44:79:02, 44:146, 44:150, 44:452:01-44:452:02, 44:459, 46:01:01:01-46:05, 46:07N-46:08, 46:10, 46:12, 46:14-46:17, 46:20, 46:22-46:24, 46:26-46:32:02, 46:34-46:42, 46:44-46:98N, 47:10, 48:05, 48:08, 48:15, 48:25, 49:01:01:01-49:10, 49:12-49:14, 49:16-49:44, 49:46-49:54, 49:56-49:80, 50:01:01:01-50:02:01:02, 50:04:01-50:22, 50:31-50:48, 50:50-50:69, 50:71-50:79, 51:01:01:01-51:04:02, 51:06:01:01-51:07:02, 51:11N-51:14, 51:16-51:18, 51:21-51:24:05, 51:26-51:30, 51:32-51:39, 51:41N, 51:43, 51:45-51:46, 51:48-51:52, 51:55-51:72, 51:74-51:80, 51:82-51:92:02, 51:94-51:96, 51:98N-51:107, 51:109-51:114, 51:116-51:119, 51:121, 51:123-51:138, 51:140, 51:142-51:147, 51:149N-51:152, 51:154-51:156, 51:158:01-51:180, 51:182-51:193:02, 51:195-51:216, 51:218-51:227, 51:229-51:258, 51:260-51:262, 51:264N-51:273N, 51:277-51:279, 51:281-51:286, 51:288-51:336, 51:339, 51:341,



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: July 2023, Rev. No:00

101.567-12 – including *Taq* polymerase  
101.567-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **2S2**

Lot-specific information

			51:343-51:353, 51:355-51:358, 51:360-51:370, 51:372-51:381, 52:01:01:01-52:01:32, 52:01:34-52:02:02, 52:04-52:09:02, 52:11:01-52:18, 52:20-52:27, 52:30-52:70, 52:72-52:73, 52:75-52:113, 53:06, 53:08:01-53:08:02, 53:28, 54:06, 54:20, 54:33, 55:01:01:01-55:01:29, 55:03, 55:05, 55:09, 55:11, 55:14-55:15, 55:17, 55:21, 55:24-55:25, 55:28:01-55:29, 55:31, 55:33, 55:36, 55:38, 55:40, 55:44-55:45, 55:52-55:53, 55:55N-55:56, 55:58-55:60, 55:64, 55:66, 55:68, 55:73-55:76, 55:78-55:79, 55:84-55:85, 55:87, 55:90-55:95, 55:97N-55:106, 55:108-55:111, 55:113-55:116, 55:118N-55:119, 55:121-55:122, 55:124-55:127, 56:03, 56:05:01-56:06, 56:21, 56:25, 56:32, 56:37, 56:66, 58:06, 58:08:01-58:08:02, 58:19, 58:46, 58:78, 58:91, 59:12, 78:01:01:02-78:03, 78:05-78:07, 78:09	
<b>10</b>	210 bp	1070 bp	*57:08	*15:403
<b>11</b>	215 bp 250 bp	<b>800 bp</b>	*57:09, 57:24, 57:119 *57:14:01-57:14:02, 57:43	*08:181
<b>12<sup>4</sup></b>	90 bp	1070 bp	*57:02:01:01-57:03:06, 57:07, 57:09, 57:12, 57:17, 57:39, 57:42, 57:46, 57:57, 57:63, 57:66, 57:70, 57:80, 57:84, 57:94, 57:96, 57:101, 57:124, 57:137, 57:155	*08:181, 40:30, 40:34
<b>13<sup>4</sup></b>	90 bp	<b>800 bp</b>	*57:01:01:01-57:01:44, 57:01:46-57:04:01, 57:04:03-57:15, 57:17- 57:19, 57:21-57:35, 57:37-57:44, 57:46- 57:50, 57:52-57:61, 57:63-57:68, 57:70- 57:88, 57:90-57:108, 57:110-57:119, 57:121-57:127, 57:129-57:167	*15:462, 58:36
<b>14</b>	135 bp 195 bp	1070 bp	*57:17 *57:10	*44:189, <b>C*07:239</b> *07:219
<b>15<sup>4,6</sup></b>	110 bp  145 bp	<b>800 bp</b>	*57:29, 57:33  *57:11	*08:301, 14:61, 15:214, 18:81, 35:250, 37:93, 39:145, 39:158, 40:427, 44:311, 44:450, 51:165, 55:108 *14:01:01:01-14:02:08, 14:02:10-14:04, 14:07N, 14:09, 14:11-14:12, 14:14-14:19, 14:21-14:36, 14:38-14:52, 14:54, 14:57- 14:70Q, 14:72N-14:95, 14:97-14:101N, 14:103-14:119, 15:510, 18:44:01-18:44:02, 35:475, 39:79, 44:440, 46:84, 50:51, 54:38, 58:02:01:01-58:02:02, 58:06-58:07, 58:25, 58:38, 58:43, 58:60, 58:104, 58:132,



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: July 2023, Rev. No:00

101.567-12 – including *Taq* polymerase  
101.567-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **2S2**

Lot-specific information

Lot No.: <b>2S2</b>		Lot-specific information		
<b>16<sup>4</sup></b>	85 bp 160 bp	1070 bp	*57:12 *57:18	<b>A*23:128, C*01:32:01-01:32:02, C*06:20, C*14:82, C*16:98, C*16:102, C*16:110</b> *08:119, 14:24, 35:226, 39:92, 58:64
<b>17</b>	140 bp 210 bp	1070 bp	*57:13, 57:31:01-57:31:02 *57:13, 57:22, 57:27, 57:57, 57:63, 57:161 <sup>w</sup>	*07:227, 08:181, 40:30, 40:34, <b>C*06:72</b> *07:227, 55:14, <b>C*06:72<sup>w</sup></b>
<b>18</b>	165 bp	1070 bp	*57:23	
<b>19<sup>4</sup></b>	90 bp 240 bp	1070 bp	*57:04:01-57:04:03, 57:41 *57:13, 57:25, 57:43	*44:153, <b>C*06:72</b> *07:227, 40:30, 40:34
<b>20<sup>4</sup></b>	90 bp 240 bp	1070 bp	*57:20 *57:26	*08:181, 55:14, <b>C*06:72</b>
<b>21<sup>4</sup></b>	120 bp 150 bp	1070 bp	*57:33, 57:98Q *57:21	*44:450 *35:127, 50:54, 55:100
<b>22<sup>4</sup></b>	95 bp 140 bp	<b>800 bp</b>	*57:34 *57:40, 57:98Q	*58:54 *14:20, 15:461, 44:317
<b>23<sup>4,7</sup></b>	75 bp 100 bp 465 bp	1070 bp	*57:35 *57:36 *57:05, 57:67:01	*15:625 *13:01:18, 13:02:06, 13:26:01, 13:72, 13:127, 15:16:03, 15:20, 15:34:02, 15:85, 15:194, 15:393, 15:407, 15:587, 15:599, 15:623, 15:658, 35:46, 35:207, 46:01:07, 46:33, 58:36, <b>C*01:73</b>
<b>24</b>	230 bp 270 bp	1070 bp	*57:77 *57:40	*15:617, 44:36, <b>A*03:174, A*11:65:01-11:65:02, A*24:247, A*29:173, C*01:170, C*04:83</b> *08:262, 15:461, 40:284, 44:317, <b>C*07:511, C*15:121, C*16:162</b>
<b>25</b>	235 bp	1070 bp	*57:44	*44:249, <b>A*24:508, A*32:29</b>
<b>26</b>	155 bp	1070 bp	*57:58, 57:80	*07:219, 58:12, <b>A*02:42:01-02:42:02, A*02:310</b>
<b>27</b>	235 bp	1070 bp	*57:61	
<b>28</b>	200 bp	1070 bp	*57:39, 57:51, 57:73	*58:41
<b>29</b>	150 bp	1070 bp	*57:78	*15:340, 35:300, 40:218, 44:307, 45:21, 46:28, 51:58, 52:82, 58:83
<b>30</b>	175 bp	1070 bp	*57:79N	
<b>31</b>	390 bp	1070 bp	*57:01:01:01-57:04:03, 57:06-57:32, 57:34-57:47, 57:49-57:66, 57:67:02-57:76, 57:78-57:84, 57:86-57:109, 57:111-57:167	*07:219, 15:16:01:01-15:16:02:02, 15:16:04, 15:17:01:01-15:17:07, 15:67, 15:95, 15:162, 15:168, 15:177, 15:196, 15:208, 15:216, 15:222, 15:230, 15:254, 15:268, 15:273, 15:356, 15:361-15:362, 15:396, 15:403, 15:408, 15:411, 15:423-15:424, 15:446, 15:462, 15:500, 15:516, 15:523, 15:532, 15:546Q, 15:550, 15:555, 15:575N, 15:602-15:603, 15:613, 15:619, 15:642, 15:644, 15:655, 58:08:01-58:08:02, 58:20, 58:27-58:28:01, 58:59:02, 58:73, 58:114
<b>32<sup>8</sup></b>	-	-	<b>Negative Control</b>	



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: July 2023, Rev. No:00

**101.567-12 – including Taq polymerase**  
**101.567-12u – without Taq polymerase**

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

**Lot No.: 2S2**

**Lot-specific information**

<sup>1</sup>Alleles are assigned by the presence of specific PCR product(s). However, the sizes of the specific PCR products may be helpful in the interpretation of HLA-B\*57 SSP typings. When the primers in a primer mix can give rise to HLA-specific PCR products of more than one length this is indicated if the size difference is more than 20 base pairs. Size differences of 20 base pairs or less are not given. For high resolution SSP kits, the alleles listed are specified according to amplicon length.

Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen. GC-rich primers have a higher tendency of giving rise to nonspecific amplifications than other primers. PCR fragments longer than the control bands may sometimes be observed. Such bands should be disregarded and do not influence the interpretation of the SSP typings. PCR fragments migrating faster than the control bands, but slower than a 400 bp fragment may be seen in some gel read-outs. Such bands can be disregarded and do not influence the interpretation of the SSP typings.

Some primers may give rise to primer oligomer artifacts. Sometimes this phenomenon is an inherent feature of the primer pair(s) of a primer mix. More often it is due to other factors such as too low amount of DNA in the PCR reactions, taking too long time in setting up the PCR reactions, working at elevated room temperature or using thermal cyclers that are not pre-heated.

<sup>2</sup>The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

In the presence of a specific amplification the intensity of the control band often decreases.

<sup>3</sup>For several HLA Class I alleles 1st and/or 4th exon(s) and beyond, as well as intron nucleotide sequences, are not available. In these instances, it is not known whether some of the primers of the SSP sets are completely matched with the target sequences or not. Assumptions is made that unknown sequences in these regions are conserved within allelic groups.

<sup>4</sup>HLA-specific PCR products shorter than 125 base pairs have a lower intensity and are less sharp than longer PCR products.

<sup>5</sup>Primer mix 9 may have tendencies of unspecific amplifications.

<sup>6</sup>Primer mix 15 has a tendency to giving rise to primer oligomer formation.

<sup>7</sup>Primer mix 23 may give rise to a lower yield of HLA-specific PCR product than the other HLA-B\*57 resolution primer mixes.

<sup>8</sup>Primer mix 32 contains a negative control, which will amplify the majority of HLA amplicons as well as the amplicons generated by the control primer pairs matching the human growth hormone gene. HLA-specific PCR product sizes range from 75 to 200 base pairs and the PCR product generated by the HGH positive control primer pair is 200 base pairs.

Abbreviations

w: might be weakly amplified.



**0197**

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: July 2023, Rev. No:00

101.567-12 – including *Taq* polymerase  
101.567-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **2S2**

Lot-specific information  
**PRIMER SPECIFICATION**

Well No.	1	2	3	4	5	6	7	8	9	10	11	12
Length of spec.	150	100	220	100	220	95	105	90	170	210	215	90
PCR product						180 205	170 295	200 250			250	
Length of int.	800	1070	1070	800	1070	1070	1070	1070	800	1070	800	1070
pos. control <sup>1</sup>												
5'-primer(s) <sup>2</sup>	355 5'-TCA 3'	362 5'-ggT 3'	362 5'-ggT 3'	355 5'-TCA 3'	362 5'-ggT 3'	362 5'-ggT 3'	209 5'-ggC 3'	97 5'-TCg 3'	527 5'-TgA 3'	320 5'-CCC 3'	362 5'-ggT 3'	362 5'-ggT 3'
							757 5'-CCA 3'	209 5'-ggA 3'				
							878 5'-gCA 3'	362 5'-ggT 3'				
3'-primer(s) <sup>3</sup>	463 5'-gCT 3'	419 5'-Cgg 3'	539 5'-TCA 3'	412 5'-gTT 3'	539 5'-TCC 3'	418 5'-gTC 3'	271 5'-CAC 3'	256 5'-CCC 3'	3 <sup>rd</sup> I 5'-TAT 3'	2 <sup>nd</sup> I 5'-TCg 3'	538 5'-gTC 3'	412 5'-gTT 3'
		419 5'-CAG 3'				500 5'-ggA 3'	916 5'-gAC 3'	572 5'-gCg 3'			559 5'-Cgg 3'	
						527 5'-CCg 3'					583 5'-gTg 3'	
Well No.	1	2	3	4	5	6	7	8	9	10	11	12

Well No.	13	14	15	16	17	18	19	20	21	22	23	24
Length of spec.	90	135	110	85	140	165	90	90	120	95	75	230
PCR product		195	145	160	210		240	240	150	140	100	270
											465	
Length of int.	800	1070	800	1070	1070	1070	1070	1070	1070	800	1070	1070
pos. control <sup>1</sup>												
5'-primer(s) <sup>2</sup>	209 5'-ggC 3'	103 5'-CCT 3'	361 5'-AgT 3'	256 5'-ACg 3'	362 5'-ggT 3'	130 5'-AgT 3'	362 5'-ggT 3'	209 5'-ggC 3'	352 5'-ACg 3'	200 5'-TCg 3'	209 5'-ggC 3'	353 5'-CAA 3'
		446 5'-CgA 3'	392 5'-CgA 3'	362 5'-ggT 3'				362 5'-ggT 3'	373 5'-gCg 3'	353 5'-CAA 3'		395 5'-gCT 3'
			704 5'-TgT 3'						392 5'-CgA 3'	373 5'-gCg 3'		
3'-primer(s) <sup>3</sup>	256 5'-CCC 3'	256 5'-CCC 3'	463 5'-gCT 3'	302 5'-ggC 3'	463 5'-gCg 3'	256 5'-CCC 3'	409 5'-ATA 3'	259 5'-CTT 3'	463 5'-gCT 3'	256 5'-CCC 3'	244 5'-CTT 3'	583 5'-gTA 3'
		539 5'-TCA 3'	774 5'-ggT 3'	481 5'-gTA 3'	527 5'-CCT 3'		559 5'-CTC 3'	559 5'-CgT 3'		463 5'-gCT 3'	268 5'-gTg 3'	
					537 5'-Agg 3'		559 5'-Cgg 3'				387 5'-TCg 3'	
Well No.	13	14	15	16	17	18	19	20	21	22	23	24



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: July 2023, Rev. No:00

101.567-12 – including *Taq* polymerase  
101.567-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **2S2**

Lot-specific information

Well No.	25	26	27	28	29	30	31
Length of spec. PCR product	235	155	235	200	150	175	390
Length of int. pos. control <sup>1</sup>	1070	1070	1070	1070	1070	1070	1070
5'-primer(s) <sup>2</sup>	122	142	362	97	106	877	281
	5'-CCT 3'	5'-TCT 3'	5'-ggT 3'	5'-TCC 3'	5'-CCA 3'	5'-AC 3'	5'-CTC 3'
3'-primer(s) <sup>3</sup>	317	256	554	256	214	916	387
	5'-ggA 3'	5'-CCC 3'	5'-CCC 3'	5'-CCC 3'	5'-CCA 3'	5'-gAC 3'	5'-TCC 3'
Well No.	25	26	27	28	29	30	31

<sup>1</sup>The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

<sup>2</sup>The nucleotide position matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

<sup>3</sup>The nucleotide position matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.



0197

101.567-12 – including Taq polymerase  
101.567-12u – without Taq polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **2S2**

Lot-specific information

				Well															
				1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
Prod. No.:				202354301	202354302	202354303	202354304	202354305	202354306	202354307	202354308	202354309	202354310	202354311	202354312	202354313	202354314	202354315	202354316
IHC cell line <sup>1</sup>		B*																	
1	9001 SA	*07:02		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
2	9280 LK707	*52:01	*73:01	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
3	9011 E4181324	*52:01		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
4	9275 GU373	*15:10	*53:01	+	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
5	9009 KAS011	*37:01		+	-	-	W	-	-	-	-	-	-	-	-	-	-	-	-
6	9353 SM	*39:01	*51:01	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
7	9020 QBL	*18:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
8	9025 DEU	*35:01		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
9	9026 YAR	*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10	9107 LKT3	*54:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11	9051 PITOUT	*44:03		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	9052 DBB	*57:01		+	+	+	-	-	-	-	-	-	-	-	-	+	-	-	-
13	9004 JESTHOM	*27:05		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	9071 OLGA	*15:01	*15:20	+	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
15	9075 DKB	*40:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
16	9037 SWEIG007	*40:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
17	9282 CTM3953540	*08:01	*55:01	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
18	9257 32367	*14:01	*56:01	-	-	-	-	-	-	-	-	-	+	-	-	-	-	+	-
19	9038 BM16	*18:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
20	9059 SLE005	*40:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
21	9064 AMALA	*15:01		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
22	9056 KOSE	*35:03		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
23	9124 IHL	*40:02	*56:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
24	9035 JBUSH	*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
25	9049 IBW9	*14:02		-	-	-	-	-	-	-	-	-	+	-	-	-	-	+	-
26	9285 WT49	*58:01		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
27	9191 CH1007	*07:05	*51:01	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
28	9320 BEL5GB	*44:02	*44:03	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
29	9050 MOU	*44:03		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
30	9021 RSH	*42:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
31	9019 DUCAF	*18:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
32	9297 HAG	*41:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
33	9098 MT14B	*40:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
34	9104 DHIF	*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
35	9302 SSTO	*44:02		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
36	9024 KT17	*15:01	*35:01	+	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
37	9065 HHKB	*07:02		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
38	9099 LZL	*15:01		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
39	9315 CML	*08:01	*27:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
40	9134 WHONP199	*13:02	*46:01	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
41	9055 H0301	*14:02		-	-	-	-	-	-	-	-	-	+	-	-	-	-	+	-
42	9066 TAB089	*46:01		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
43	9076 T7526	*46:01		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
44	9057 TEM	*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
45	9239 SHJO	*42:01	*50:01	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
46	9013 SCHU	*07:02		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
47	9045 TUBO	*51:01		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
48	9303 TER-ND	*35:01	*44:03	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: July 2023, Rev. No:00

101.567-12 – including *Taq* polymerase  
101.567-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **2S2**

Lot-specific information

<b>CELL LINE VALIDATION SHEET</b>																			
<b>HLA-B*57 SSP subtyping kit<sup>2</sup></b>																			
			Prod. No.:	Well															
				17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	
				202354317	202354318	202354319	202354320	202354321	202354322	202354323	202354324	202354325	202354326	202354327	202354328	202354329	202354330	202354331	
	IHWC cell line <sup>1</sup>	B*																	
1	9001 SA	*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
2	9280 LK707	*52:01 *73:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
3	9011 E4181324	*52:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
4	9275 GU373	*15:10 *53:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
5	9009 KAS011	*37:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
6	9353 SM	*39:01 *51:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
7	9020 QBL	*18:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
8	9025 DEU	*35:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
9	9026 YAR	*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
10	9107 LKT3	*54:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
11	9051 PITOUT	*44:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
12	9052 DBB	*57:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	
13	9004 JESTHOM	*27:05		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
14	9071 OLGA	*15:01 *15:20		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	
15	9075 DKB	*40:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
16	9037 SWEIG007	*40:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
17	9282 CTM3953540	*08:01 *55:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
18	9257 32367	*14:01 *56:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
19	9038 BM16	*18:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
20	9059 SLE005	*40:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
21	9064 AMALA	*15:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
22	9056 KOSE	*35:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
23	9124 IHL	*40:02 *56:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
24	9035 JBUSH	*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
25	9049 IBW9	*14:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
26	9285 WT49	*58:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
27	9191 CH1007	*07:05 *51:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
28	9320 BEL5GB	*44:02 *44:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
29	9050 MOU	*44:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
30	9021 RSH	*42:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
31	9019 DUCAF	*18:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
32	9297 HAG	*41:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
33	9098 MT14B	*40:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
34	9104 DHIF	*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
35	9302 SSTO	*44:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
36	9024 KT17	*15:01 *35:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
37	9065 HHKB	*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
38	9099 LZL	*15:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
39	9315 CML	*08:01 *27:05		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
40	9134 WHONP199	*13:02 *46:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
41	9055 H0301	*14:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
42	9066 TAB089	*46:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
43	9076 T7526	*46:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
44	9057 TEM	*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
45	9239 SHJO	*42:01 *50:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
46	9013 SCHU	*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
47	9045 TUBO	*51:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
48	9303 TER-ND	*35:01 *44:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	



0197



**101.567-12 – including Taq polymerase**  
**101.567-12u – without Taq polymerase**

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

**Lot No.: 2S2**

**Lot-specific information**

<sup>1</sup>The provided cell line HLA specificities are retrieved from the <http://www.ihwg.org/hla> web site. The specificity of an individual cell line may thus be subject to change.

<sup>2</sup>The specificity of each primer solution in the kit has been tested against 48 well characterized cell line DNAs and where applicable, additional cell line DNAs.

No DNAs carrying the alleles to be amplified by primer solutions 6 to 8, 11, 14, 16 to 22 and 24 to 30 were available. The specificities of the primers in primer solutions 6 to 8, 11, 14, 16, 17, 19, 20, 26 and 28 were tested by separately adding additional 5'-primers or additional 3'-primers, respectively. In primer solutions 27 and 29 it was only possible to test the 5'-primer, the 3'-primer was not possible to be tested. In primer solutions 18, 21, 22, 24, 25 and 30 it was only possible to test the 3'-primers, the 5'-primers were not possible to be tested.

In primer solutions 2, 6, 7, 11, 16, 17, 19, 20 and 23 one or two of the 3'-primers were not possible to be tested, and in primer solutions 7, 8, 14 and 15 one or two of the 5'-primers were not possible to be tested. In addition, one 3'-primer in primer solution 15 was tested by separately adding one 5'-primer.



**0197**

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: July 2023, Rev. No:00

101.567-12 – including *Taq* polymerase  
101.567-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **2S2**

Lot-specific information

**ADDRESSES:**

**Manufacturer:**

**CareDx AB**, Franzengatan 5, SE-112 51 Stockholm, Sweden.

Tel: +46-8-508 939 00

**Fax:** +46-8-717 88 18

**E-mail:** [orders-se@caredx.com](mailto:orders-se@caredx.com)

**Web page:** [www.caredx.com](http://www.caredx.com)

**CareDx Lab Solutions Inc.**, 901 S. Bolmar St., Suite R, West Chester, PA 19382

Tel: 1-877-653-78171

**Fax:** 610-344-7989

**E-mail:** [orders-us@caredx.com](mailto:orders-us@caredx.com)

**Web page:** [www.caredx.com](http://www.caredx.com)

For information on CareDx distributors worldwide, contact **CareDx AB**.



**0197**

For *In Vitro* Diagnostic Use

MA123 v02 SSP PI Template

Date: July 2023, Rev. No:00